[HTML][HTML] Impact of new drugs for therapeutic intervention in Alzheimer's disease

J Olloquequi, M Ettcheto, A Cano… - Frontiers in Bioscience …, 2022 - imrpress.com
The increases in population ageing and growth are leading to a boosting in the number of
people living with dementia, Alzheimer's disease (AD) being the most common cause. In …

Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions

A Abeysinghe, R Deshapriya, C Udawatte - Life sciences, 2020 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …

Novel therapeutic approaches for Alzheimer's disease: an updated review

TW Yu, HY Lane, CH Lin - International journal of molecular sciences, 2021 - mdpi.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for
most cases of dementia. The prevalence of AD has increased in the current rapidly aging …

Alzheimer's disease hypothesis and related therapies

X Du, X Wang, M Geng - Translational neurodegeneration, 2018 - Springer
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most
common cause for dementia. There are many hypotheses about AD, including abnormal …

Comprehensive review on Alzheimer's disease: causes and treatment

Z Breijyeh, R Karaman - Molecules, 2020 - mdpi.com
Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and
it is the main cause of dementia, which is characterized by a decline in thinking and …

[HTML][HTML] Small-molecule drugs development for Alzheimer's disease

W Yao, H Yang, J Yang - Frontiers in Aging Neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative brain disorder
with no effective therapeutic drugs currently. The complicated pathophysiology of AD is not …

Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors

YC Kuo, R Rajesh - Expert review of neurotherapeutics, 2019 - Taylor & Francis
Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative
disorder, causes cognitive decline and has a devastating effect on the quality of life. AD …

Alzheimer's disease: molecular aspects and treatment opportunities using herbal drugs

S Thakral, A Yadav, V Singh, M Kumar, P Kumar… - Ageing Research …, 2023 - Elsevier
Abstract Alzheimer's disease (AD), also called senile dementia, is the most common
neurological disorder. Around 50 million people, mostly of advanced age, are suffering from …

Recent update on the Alzheimer's disease progression, diagnosis and treatment approaches

A Malaiya, M Singhai, M Singh, SK Prajapati… - Current Drug …, 2022 - ingentaconnect.com
Alzheimer's disease (AD) is a multifactorial, progressive, neurodegenerative disorder,
manifested by the loss of memory and cognitive abilities, behavioral disturbance and …

An update on pharmacological approaches to neurodegenerative diseases

R Scatena, GE Martorana, P Bottoni… - Expert opinion on …, 2007 - Taylor & Francis
Neurodegenerative diseases are now generally considered as a group of disorders that
seriously and progressively impair the functions of the nervous system through selective …